Removing barriers
to a larger national investment in
chemoprevention drug development
2008
Executive Summary & Recommendations
Chemoprevention Strategic Initiative Goals

The C-Change Cancer Chemoprevention Research initiative aims to resolve major barriers -- limitations in patent and intellectual property law; uncertainty of reimbursement; lengthy clinical trial processes involving the emerging science of biomarkers; and the uncharted regulatory approval process -- to stimulate an increased intellectual and financial investment in chemoprevention and cancer vaccine research.

By accelerating the development of promising chemoprevention agents, cancer can be prevented.

About C-Change

C-Change is a not-for-profit organization whose mission is to eliminate cancer as a public health problem, at the earliest possible time, by leveraging the expertise and resources of our members. C-Change is the only organization that assembles cancer leaders from the three sectors – private, public, and not-for-profit – from across the cancer continuum – prevention, early detection, treatment, and quality of life.

Former President George Bush and former First Lady Barbara Bush are Co-chairs of C-Change and Senator Dianne Feinstein serves as Vice Chair of C-Change, a 501(c)(3). C-Change is comprised of approximately 130 of the Nation's key cancer leaders who share the vision of a future where cancer is prevented, detected early, and cured or is managed successfully as a chronic illness.

One of the underlying principles of C-Change is to serve as both a forum and a catalyst for identifying issues and major challenges facing the cancer community, and for initiating collaborative actions to complement the efforts of individual C-Change Members. C-Change invests in the resolution of problems that cannot be solved by one organization or one sector alone.
Executive Summary & Recommendations

Introduction
At C-Change, we envision a future where cancer is prevented, detected early, and cured or managed successfully as a chronic illness. We recognize that enabling the promise of emerging research in chemoprevention is one key element in achieving this end. Several major systemic barriers currently deter further investment in the research and development of chemopreventive agents: 1) the limited life of patents in agents requiring a prolonged development time due to their preventive nature; 2) the uncertainty of reimbursement; and 3) an uncharted clinical trial design and regulatory approval process.

Background
In 2006, C-Change hosted a summit of multidisciplinary experts and leaders to further define the barriers and potential solutions facing the field of chemoprevention. Several major systemic barriers were identified as major deterrents to further intellectual and financial investment in the research and development of chemopreventive and immunoprevention agents: 1) the limited life of patents in agents requiring a prolonged development time due to their preventive nature; 2) the uncertainty of reimbursement; and 3) an uncharted clinical trial design and regulatory approval process.

A summary of the summit proceedings is contained in the following journal publication:


Since the summit, an advisory committee and several sub-committees have developed and/or commissioned white papers proposing solutions to these patent law, reimbursement, and regulatory/scientific barriers. Below is a summary of the proposed solutions which are informed by these collaborative works by C-Change as well as an industry survey that was performed by Friends of Cancer Research.

Patent Law

Recommendations for removing the barrier posed by patent law are based upon the following documents:


Executive Summary & Recommendations

Patent Law (continued)

Recommendations for legislative action, encouragement, and/or agency encouragement:

- Congress should give positive consideration to lengthening the data exclusivity period for new chemo-prevention, biologic prevention, or immunoprevention agents to 14 years.
- Proposals for an abbreviated regulatory approval process for follow-on biologics must not simply mirror the 1984 Hatch-Waxman Statute. Policymakers must give careful consideration to the significant scientific differences between chemical and biological agents that, among other things, make establishing equivalence very difficult. The failure to understand this, could lead to unintended adverse clinical outcomes and compromise drug safety.
- If legislation providing an abbreviated approval process for biopharmaceuticals is considered, it should include a substantial period of data exclusivity.
- In considering patent law reform, Congress should carefully weigh the impact of such proposed reforms on the incentive system for new drug research and development. While we strongly support steps to enhance the quality of patents and reduce the cost of patent litigation, we do not support provisions that add to the risk and cost of drug research or reduce the deterrents to infringement.
- Targeted incentives such as those included in the Orphan Drug Act should be extended to the development of chemoprevention or other types of prevention agents for cancer. This would include the 50 percent tax credit for clinical trials and FDA input regarding clinical trial protocols. Consideration should also be given to some period of market exclusivity protection balanced against the interests of competition and new research.

Reimbursement

Recommendations for removing the barriers posed by the uncertainty of reimbursement are based upon the following document:


Recommendations for legislative action, encouragement, and/or agency encouragement:

- CMS should provide benefit coverage for approved cancer preventive agents and sponsor demonstration projects with newly approved cancer preventive agents to reduce the uncertainty of reimbursement for developers and to evaluate the long term economic value of cancer preventive agent regimens.
Executive Summary & Recommendations

Clinical Trials / Regulatory Approval

Recommendations for removing the barrier posed by the uncertainty of reimbursement are based upon the following document:


Recommendations for legislative action, encouragement, and/or agency encouragement:

- FDA should define guidelines, criteria, and/or procedures for chemopreventive drugs and immunologic or other biologic preventive agents for:
  - Qualifying biomarkers as indications for agent use as well as agent efficacy, and safety
  - Utilizing biomarkers in cancer preventive clinical trial design
  - Advancing clinical trials from initial, proof of concept phase II trials in subjects with very high risk for developing invasive cancer to large scale phase III trials in populations with moderately or highly increased risk for developing invasive cancer
  - Defining parameters for acceptable drug side effect profiles for preventive cancer agents among populations at differing risk for developing cancer
- Congress should provide substantially increasing funding for preclinical and clinical research to develop promising and innovative agents for prevention of cancer, and for identifying and validating biomarkers to facilitate the development and appropriate application of preventive agents to the relevant populations.
Acknowledgement

C-Change wishes to thank the leaders from the private, public, and not-for-profit sectors who collaborated to advance this emerging field of cancer chemoprevention research. Without their expertise and cooperation, these thoughtful works and the actions based upon them would not have been possible. In addition to all of the contributors listed below, C-Change would like to specially acknowledge Dr. Ronald Herberman who has tirelessly led this complex initiative. C-Change would also like to recognize the leadership of the sub-group committee chairs, Catherine Bennett, Bruce Pyenson, Dr. Frank Meyskens, and Dr. Gregory Curt.

All C-Change committee members participated voluntarily. The participation of federal agency employees was limited to providing information regarding existing policies and practices and providing expertise on scientific matters.

Chemoprevention Advisory Committee

Ron Herberman, Chair
University of Pittsburgh Cancer Institute
Carolyn (Bo) Aldige
Cancer Research and Prevention Foundation
Anna Barker
National Cancer Institute
Gregory Curt
AstraZeneca
Marge Foti
American Association of Cancer Research
Gary Gordon
Abbott
Mark Mendenhall
American Association for Cancer Research
Homer Pearce
Eli Lilly, retired
Eddie Reed
Centers For Disease Control And Prevention
Ellen Sigal
Friends of Cancer Research
Robert Young
Fox Chase Cancer Center
Janet Woodcock
Food & Drug Administration

Chemoprevention Patent Law Advisory Sub-Committee

Catherine Bennett, Chair
National Foreign Trade Council
Jeff Allen
Friends of Cancer Research
Daniel Kracov
Arnold and Porter LLP
Mark Mendenhall
American Association of Cancer Research
Homer Pearce
Eli Lilly and Company (retired)
Caroline Sigman
CCS Associates
Mark Smith
King & Spalding LLP
Gavin Zealey
Sanofi Pasteur
**Leadership & Collaboration**

**Chemoprevention Reimbursement Sub-Committee**

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruce Pyenson, Chair</td>
<td>Milliman, Inc</td>
</tr>
<tr>
<td>Kathryn Phillips-Campbell</td>
<td>National Business Group on Health</td>
</tr>
<tr>
<td>Scott Ramsey</td>
<td>Fred Hutchinson Cancer Research Center</td>
</tr>
<tr>
<td>Jayson Slotnik</td>
<td>Hogan &amp; Hartson</td>
</tr>
<tr>
<td>Robin Zon</td>
<td>American Society for Clinical Oncology</td>
</tr>
</tbody>
</table>

**Chemoprevention Clinical Trials & Biomarkers Sub-Committee**

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Curt, Co-Chair</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Frank Meyskens, Co-Chair</td>
<td>University of California – Irvine</td>
</tr>
<tr>
<td>Dean Brenner</td>
<td>University of Michigan</td>
</tr>
<tr>
<td>Powell Brown</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>James Crowell</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Jack Cusik</td>
<td>Cancer Research UK</td>
</tr>
<tr>
<td>Bob Dorr</td>
<td>University of Arizona</td>
</tr>
<tr>
<td>Craig Eagle</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Scott Emerson</td>
<td>Fred Hutchinson Cancer Center</td>
</tr>
<tr>
<td>Olivera Finn</td>
<td>University of Pittsburgh Cancer Institute</td>
</tr>
<tr>
<td>Neil Gibson</td>
<td>OSI Pharmaceuticals</td>
</tr>
<tr>
<td>Gary Gordon</td>
<td>Abbott Laboratories</td>
</tr>
<tr>
<td>Ernie Hawk</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Ron Herberman</td>
<td>University of Pittsburgh Cancer Institute</td>
</tr>
<tr>
<td>Gary Kelloff</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Samir Khrief</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Scott Lippman</td>
<td>MD Anderson Cancer Institute</td>
</tr>
<tr>
<td>Christine McLaren</td>
<td>University of California, Irvine</td>
</tr>
<tr>
<td>Colleen Mockbee</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Clet Niyikiza</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Dave Parkinson</td>
<td>Amgen</td>
</tr>
<tr>
<td>Joe Purvis</td>
<td>Astra Zeneca</td>
</tr>
<tr>
<td>Caroline Sigman</td>
<td>CCS Associates</td>
</tr>
<tr>
<td>Eva Szabo</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Victor Vogel</td>
<td>University of Pittsburgh Cancer Institute, NSABP</td>
</tr>
<tr>
<td>Lou Weiner</td>
<td>Lombardi Cancer Center, Georgetown University</td>
</tr>
<tr>
<td>Bob Young</td>
<td>Fox Chase Cancer Center</td>
</tr>
</tbody>
</table>